AR and prostate carcinoma: In addition, in recent years, many non-targeted AR pathway therapies, such as PARP inhibitor or immune therapy [41–43], have been explored and discovered, aiming to explore new ways of prostate cancer treatment and combination drugs to enhance the therapeutic effect.